Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0034 Transporter Info
Gene Name	SLC18A2
Transporter Name	Vesicular amine transporter 2
Gene ID	6571
UniProt ID	Q05940

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Tetrabenazine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Tetrabenazine results in decreased activity of SLC18A2 protein		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Dopamine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Dopamine results in decreased activity of SLC18A2 protein		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Heptachlor Epoxide inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	para-methyl-4-methylaminorex inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Reserpine inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Norepinephrine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Norepinephrine results in decreased activity of SLC18A2 protein		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	pyrazolanthrone inhibits the reaction Rotenone results in decreased activity of SLC18A2 protein		[10]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Rotenone results in decreased activity of SLC18A2 protein		[10]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Methylphenidate results in decreased activity of SLC18A2 protein		[15]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Methamphetamine results in decreased activity of SLC18A2 protein		[15]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Valproic Acid affects the expression of SLC18A2 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Valproic Acid results in decreased methylation of SLC18A2 gene		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Reserpine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Reserpine inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Reserpine results in decreased activity of SLC18A2 protein		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	SLC18A2 gene SNP results in decreased susceptibility to Reserpine		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
aroclor 1260	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	aroclor 1260 results in decreased activity of SLC18A2 protein		[15]
Regulation Mechanism			Transcription Factor Info
Benzo(a)pyrene	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC18A2 intron		[29]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in increased methylation of SLC18A2 5' UTR		[30]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Benzo(a)pyrene results in increased methylation of SLC18A2 promoter		[30]
Regulation Mechanism			Transcription Factor Info
bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in increased methylation of SLC18A2 gene		[31]
Regulation Mechanism			Transcription Factor Info
Calcitriol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Calcitriol inhibits the reaction VDR protein results in increased expression of SLC18A2 mRNA		[32]
Regulation Mechanism			Transcription Factor Info
Catechin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Catechin co-treated with Grape Seed Proanthocyanidins results in decreased expression of SLC18A2 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC18A2 gene		[34]
Regulation Mechanism			Transcription Factor Info
Dextroamphetamine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dextroamphetamine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
Dichlorodiphenyl Dichloroethylene	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dichlorodiphenyl Dichloroethylene results in increased expression of SLC18A2 mRNA		[36]
Regulation Mechanism			Transcription Factor Info
di-n-butylphosphoric acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	di-n-butylphosphoric acid affects the expression of SLC18A2 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
dorsomorphin	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
entinostat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	entinostat results in increased expression of SLC18A2 mRNA		[17]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
Fulvestrant	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in increased methylation of SLC18A2 gene		[31]
Regulation Mechanism			Transcription Factor Info
Haloperidol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Haloperidol binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
Heptachlor Epoxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Heptachlor Epoxide inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[38]
Regulation Mechanism			Transcription Factor Info
Histamine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Histamine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
Mazindol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Mazindol binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
mercuric bromide	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	mercuric bromide results in decreased expression of SLC18A2 mRNA		[17]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC18A2 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
N-Methyl-3,4-methylenedioxyamphetamine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
Nomifensine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Nomifensine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
para-methyl-4-methylaminorex	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	para-methyl-4-methylaminorex inhibits the reaction SLC18A2 protein results in increased uptake of Dopamine		[39]
Regulation Mechanism			Transcription Factor Info
pentabromodiphenyl ether	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	pentabromodiphenyl ether results in decreased activity of SLC18A2 protein		[40]
Regulation Mechanism			Transcription Factor Info
pyrazolanthrone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	pyrazolanthrone inhibits the reaction Rotenone results in decreased activity of SLC18A2 protein		[10]
Regulation Mechanism			Transcription Factor Info
Serotonin	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Serotonin binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC18A2 gene SNP affects the uptake of Serotonin		[8]
Regulation Mechanism			Transcription Factor Info
trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	trichostatin A results in increased expression of SLC18A2 mRNA		[19]
Regulation Mechanism			Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC18A2 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
valbenazine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	valbenazine results in decreased activity of SLC18A2 protein		[14]
Regulation Mechanism			Transcription Factor Info
vanoxerine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	vanoxerine binds to SLC18A2 protein		[35]
Regulation Mechanism			Transcription Factor Info
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 results in increased methylation of SLC18A2 intron		[29]
Regulation Mechanism			Transcription Factor Info
aflatoxin B2	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	aflatoxin B2 results in increased methylation of SLC18A2 intron		[29]
Regulation Mechanism			Transcription Factor Info
Herbicide
DT Modulation1	Paraquat results in decreased activity of SLC18A2 protein		[15]
Regulation Mechanism			Transcription Factor Info
Approved Drug
Tetrabenazine	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tetrabenazine blocks the activity of SLC18A2		[1], [2]
DT Modulation2	Tetrabenazine inhibits the activity of SLC18A2		[4]
Deutetrabenazine	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Deutetrabenazine modulates the activity of SLC18A2		[3]
DT Modulation2	Deutetrabenazine inhibits the activity of SLC18A2		[5]
Cocaine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the expression of SLC18A2		[6]
Dexamethasone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dexamethasone increases the expression of SLC18A2		[7]
Dopamine	8 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dopamine inhibits the activity of SLC18A2		[8]
Norepinephrine	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Norepinephrine inhibits the activity of SLC18A2		[8]
Carbamazepine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Carbamazepine affects the expression of SLC18A2		[11]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Acetaminophen increases the expression of SLC18A2		[12]
Leflunomide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Leflunomide inhibits the expression of SLC18A2		[13]
Valbenazine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valbenazine inhibits the activity of SLC18A2		[14]
Methylphenidate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methylphenidate inhibits the activity of SLC18A2		[15]
Methamphetamine	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methamphetamine inhibits the expression of SLC18A2		[16]
Valproic Acid	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valproic Acid increases the expression of SLC18A2		[17]
Reserpine	5 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Reserpine blocks the activity of SLC18A2		[2]
Alkavervir	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Alkavervir modulates the activity of SLC18A2		[3]
Valbenazine tosylate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valbenazine tosylate modulates the activity of SLC18A2		[3]
Alseroxylon	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Alseroxylon blocks the activity of SLC18A2		[18]
Drug Marketed but not Approved by US FDA
Arbutin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Arbutin inhibits the expression of SLC18A2		[9]
Rotenone	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Rotenone inhibits the activity of SLC18A2		[10]
Drug in Phase 3 Trial
AV-133	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	AV 133 enhances the activity of SLC18A2		[26]
NBI-98854	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NBI-98854 inhibits the activity of SLC18A2		[28]
Drug in Phase 2 Trial
MS-275	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	MS-275 increases the expression of SLC18A2		[24]
Lobeline	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Lobeline inhibits the activity of SLC18A2		[27]
Drug in Phase 1 Trial
Trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Trichostatin A increases the expression of SLC18A2		[19]
SOM3355	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SOM3355 inhibits the activity of SLC18A2		[25]
Investigative Drug
Phenylmercuric Acetate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Phenylmercuric Acetate inhibits the expression of SLC18A2		[17]
Patented Pharmaceutical Agent
GSK-J4	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	GSK-J4 increases the expression of SLC18A2		[21]
Natural Product
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution increases the expression of SLC18A2		[23]
Traditional Medicine
Jinfukang	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Jinfukang inhibits the expression of SLC18A2		[20]
Acute Toxic Substance
Paraquat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Paraquat inhibits the activity of SLC18A2		[15]
Antimycin A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Antimycin A increases the expression of SLC18A2		[22]

References
1	11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009 Mar;50(3):382-9.
2	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Deutetrabenazine Therapy and CYP2D6 Genotype.
5	Deutetrabenazine in Tics Associated with Tourette Syndrome. Tremor Other Hyperkinet Mov (N Y). 2016 Nov 7;6:422. eCollection 2016.
6	Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry. 2003 Jan;160(1):47-55.
7	Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
8	The effect of rare human sequence variants on the function of vesicular monoamine transporter 2. Pharmacogenetics. 2004 Sep;14(9):587-94.
9	Toxicogenomics of A375 human malignant melanoma cells treated with arbutin. J Biomed Sci. 2007 Jan;14(1):87-105.
10	JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death. Toxicology. 2015 Feb 3;328:75-81.
11	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
12	Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
13	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
14	Valbenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag. 2019 Apr;9(2):73-81.
15	Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters. Chem Res Toxicol. 2021 May 17;34(5):1256-1264.
16	Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med. 2007 May;121(3):163-8.
17	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
18	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
19	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
20	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
21	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018 Feb 16;293(7):2422-2437.
22	Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615.
23	Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
24	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
25	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
26	Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
27	Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
28	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
29	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
30	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
31	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
32	Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience. 2016;333:193-203.
33	Dietary flavanols modulate the transcription of genes associated with cardiovascular pathology without changes in their DNA methylation state. PLoS One. 2014;9(4):e95527.
34	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
35	Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994;22(1-4):219-26.
36	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
37	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
38	Heptachlor alters expression and function of dopamine transporters. Neurotoxicology. 1999;20(4):631-7.
39	The psychostimulant ()-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018;138:282-291.
40	Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: role of dopamine handling in neurotoxicity. Exp Neurol. 2013;241:138-47.
41	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence